Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | CES2 | O00748 | 2/20 | 0.39 |
| ▸ | CES1 | P23141 | 2/20 | 0.39 |
| ▸ | CA3 | P07451 | 1/20 | 0.39 |
| ▸ | CA6 | P23280 | 1/20 | 0.39 |
| ▸ | CA5A | P35218 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.39 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.38 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.35 |
| ▸ | IDO1 | P14902 | 2/20 | 0.35 |
| ▸ | AGXT | P21549 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4307281 | 0.86 | ALDH1A1 (0.46) | ALDH1A1CES2CES1CA3CA6 | |
| SCHEMBL5261755 | 0.80 | DDB1 (0.42) | ALDH1A1CES2CES1CA3CA6 | |
| SCHEMBL21279547 | 0.77 | ALDH1A1 (0.42) | ALDH1A1CES2CES1CA3CA6 | |
| SCHEMBL5716211 | 0.77 | DDB1 (0.44) | ALDH1A1CES2CES1CA3CA6 | |
| SCHEMBL5531618 | 0.77 | ALDH1A1 (0.42) | ALDH1A1CES2CES1CA3CA6 | |
| SCHEMBL13338139 | 0.77 | DDB1 (0.44) | ALDH1A1CES2CES1CA3CA6 | |
| SCHEMBL14469220 | 0.75 | DDB1 (0.42) | ALDH1A1CES2CES1CA3CA6 | |
| SCHEMBL979334 | 0.75 | DGAT1 (0.41) | ALDH1A1CYP2A6 | |
| SCHEMBL6692254 | 0.75 | MAP2K2 (0.30) | — | |
| Hydrochloric Acid SCHEMBL31098507 | 0.75 | DDB1 (0.42) | ALDH1A1CES2CES1CA3CA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007126262-A1 | ANION RECEPTOR, AND ELECTROLYTE USING THE SAME | KYUNGWON ENTERPRISE CO., LTD. (KR) | 2007-11-08 | — | — | WO | claimed |
| US-11168086-B2 | Methods of synthesizing pyrazine compounds | HOFFMANN-LA ROCHE INC. (US) | 2021-11-09 | — | — | US | disclosed |
| US-20180334461-A1 | NOVEL PYRAZINE COMPOUNDS FOR THE TREATMENT OF INFECTIOUS DISEASES | HOFFMANN-LA ROCHE INC. (US) | 2018-11-22 | — | — | US | disclosed |
| US-9890167-B2 | Pyrazine compounds for the treatment of infectious diseases | HOFFMANN-LA ROCHE INC. (US) | 2018-02-13 | — | — | US | disclosed |
| EP-3245206-A1 | PYRAZINE COMPOUNDS FOR THE TREATMENT OF INFECTIOUS DISEASES | F. Hoffmann-La Roche AG (CH) | 2017-11-22 | — | — | EP | disclosed |
| US-20160237090-A1 | NOVEL PYRAZINE COMPOUNDS FOR THE TREATMENT OF INFECTIOUS DISEASES | HOFFMANN-LA ROCHE INC. (US) | 2016-08-18 | — | — | US | disclosed |
| WO-2016113273-A1 | PYRAZINE COMPOUNDS FOR THE TREATMENT OF INFECTIOUS DISEASES | F. HOFFMANN-LA ROCHE AG (CH) | 2016-07-21 | — | — | WO | disclosed |
| US-20120172386-A1 | Combinations Comprising a VEGF Receptor Inhibitor | NOVARTIS AG (CH) | 2012-07-05 | — | — | US | disclosed |
| EP-1945217-B1 | COMBINATIONS COMPRISING A VEGF RECEPTOR INHIBITOR AND A PENETRATION ENHANCER | NOVARTIS AG (CH) | 2012-05-02 | — | — | EP | disclosed |
| US-20110301157-A1 | BICYCLIC AMIDES AS KINASE INHIBITORS | NOVARTIS AG | 2011-12-08 | — | — | US | disclosed |
| US-8026247-B2 | Bicyclic amides as kinase inhibitors | NOVARTIS AG (CH) | 2011-09-27 | — | — | US | disclosed |
| US-20080306058-A1 | Combinations Comprising a Vegf Receptor Inhibitor | NOVARTIS AG | 2008-12-11 | — | — | US | disclosed |
| US-20080287427-A1 | Bicyclic Amides as Kinase Inhibitors | NOVARTIS AG (CH) | 2008-11-20 | — | — | US | disclosed |
| EP-1945217-A2 | COMBINATIONS COMPRISING A VEGF RECEPTOR INHIBITOR AND A PENETRATION ENHANCER | Novartis AG (CH) | 2008-07-23 | — | — | EP | disclosed |
| WO-2007126262-A1 | ANION RECEPTOR, AND ELECTROLYTE USING THE SAME | KYUNGWON ENTERPRISE CO., LTD. (KR) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007126262-A1 | ANION RECEPTOR, AND ELECTROLYTE USING THE SAME | KYUNGWON ENTERPRISE CO., LTD. (KR) | 2007-11-08 | — | — | WO | disclosed |
| EP-1794149-A2 | BICYCLIC AMIDES AS KINASE INHIBITORS | Novartis AG (CH) | 2007-06-13 | — | — | EP | disclosed |
| WO-2007031265-A2 | COMBINATIONS COMPRISING A VEGF RECEPTOR INHIBITOR AND A PENETRATION ENHANCER | NOVARTIS AG (CH) | 2007-03-22 | — | — | WO | disclosed |
| WO-2006059234-A2 | BICYCLIC AMIDES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2006-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306058-A1 | Combinations Comprising a Vegf Receptor Inhibitor | KDR, FLT4, FLT1 | ALDH1A1 3232/4885CES2 3825/4885CES1 3021/4885 |
| US-11168086-B2 | Methods of synthesizing pyrazine compounds | CYP3A5, HAVCR2, HCCS | ALDH1A1 750/4885CES2 896/4885CES1 237/4885 |
| US-20110301157-A1 | BICYCLIC AMIDES AS KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K19 | ALDH1A1 2819/4885CES2 2900/4885CES1 1571/4885 |
| US-20160237090-A1 | NOVEL PYRAZINE COMPOUNDS FOR THE TREATMENT OF INFECTIOUS DISEASES | HAVCR2, NR1H4, ZC3HAV1 | ALDH1A1 769/4885CES2 1907/4885CES1 224/4885 |
| US-20180334461-A1 | NOVEL PYRAZINE COMPOUNDS FOR THE TREATMENT OF INFECTIOUS DISEASES | HAVCR2, NR1H4, ZC3HAV1 | ALDH1A1 769/4885CES2 1907/4885CES1 224/4885 |
| US-20080287427-A1 | Bicyclic Amides as Kinase Inhibitors | MAP3K20, MAP3K1, MAP3K19 | ALDH1A1 3019/4885CES2 3135/4885CES1 1664/4885 |
| US-20120172386-A1 | Combinations Comprising a VEGF Receptor Inhibitor | KDR, FLT4, FLT1 | ALDH1A1 3232/4885CES2 3825/4885CES1 3021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.